Fulcrum Therapeutics Net Worth
Fulcrum Therapeutics Net Worth Breakdown | FULC |
Fulcrum Therapeutics Net Worth Analysis
Fulcrum Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Fulcrum Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Fulcrum Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Fulcrum Therapeutics' net worth analysis. One common approach is to calculate Fulcrum Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Fulcrum Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Fulcrum Therapeutics' net worth. This approach calculates the present value of Fulcrum Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Fulcrum Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Fulcrum Therapeutics' net worth. This involves comparing Fulcrum Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Fulcrum Therapeutics' net worth relative to its peers.
To determine if Fulcrum Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Fulcrum Therapeutics' net worth research are outlined below:
| Fulcrum Therapeutics generated a negative expected return over the last 90 days | |
| Fulcrum Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 2.81 M. Net Loss for the year was (97.33 M) with loss before overhead, payroll, taxes, and interest of (70.44 M). | |
| Fulcrum Therapeutics currently holds about 221.79 M in cash with (90.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 90.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Brokerages Set Fulcrum Therapeutics, Inc. Price Target at 9.33 - MarketBeat |
Fulcrum Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Fulcrum Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Fulcrum Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Fulcrum Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Fulcrum Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Fulcrum Therapeutics backward and forwards among themselves. Fulcrum Therapeutics' institutional investor refers to the entity that pools money to purchase Fulcrum Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.4 M | Citadel Advisors Llc | 2024-09-30 | 1.3 M | Geode Capital Management, Llc | 2024-09-30 | 1.3 M | Vestal Point Capital Lp | 2024-06-30 | 1.2 M | Braidwell Lp | 2024-09-30 | 1.1 M | State Street Corp | 2024-06-30 | 1 M | Deutsche Bank Ag | 2024-06-30 | 849.2 K | D. E. Shaw & Co Lp | 2024-09-30 | 757.7 K | Propel Bio Management Llc | 2024-06-30 | 750 K | Ra Capital Management, Llc | 2024-09-30 | 10.2 M | Rtw Investments, Llc | 2024-06-30 | 5.8 M |
Follow Fulcrum Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 175.3 M.Market Cap |
|
Project Fulcrum Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.45) | (0.48) | |
| Return On Assets | (0.38) | (0.40) | |
| Return On Equity | (0.41) | (0.43) |
When accessing Fulcrum Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Fulcrum Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Fulcrum Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Fulcrum Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Fulcrum Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Fulcrum Therapeutics' management manipulating its earnings.
Evaluate Fulcrum Therapeutics' management efficiency
Fulcrum Therapeutics has return on total asset (ROA) of (0.0689) % which means that it has lost $0.0689 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0737) %, meaning that it created substantial loss on money invested by shareholders. Fulcrum Therapeutics' management efficiency ratios could be used to measure how well Fulcrum Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -0.4. In addition to that, Return On Capital Employed is expected to decline to -0.48. At present, Fulcrum Therapeutics' Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 3.9 M, whereas Total Assets are forecasted to decline to about 164.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.84 | 3.49 | |
| Tangible Book Value Per Share | 3.84 | 3.49 | |
| Enterprise Value Over EBITDA | (3.68) | (3.86) | |
| Price Book Value Ratio | 1.76 | 1.67 | |
| Enterprise Value Multiple | (3.68) | (3.86) | |
| Price Fair Value | 1.76 | 1.67 |
The decision-making processes within Fulcrum Therapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 117.3999 | Revenue 81.6 M | Quarterly Revenue Growth 89.909 | Revenue Per Share 1.317 | Return On Equity (0.07) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fulcrum Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fulcrum Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Fulcrum Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Fulcrum Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F3 | 23rd of September 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Fulcrum Therapeutics Earnings per Share Projection vs Actual
Fulcrum Therapeutics Corporate Management
| Rudolf MD | Founder | Profile | |
| CPA CMA | Chief Officer | Profile | |
| Jeffrey Jacobs | Chief Officer | Profile | |
| Mel Hayes | Executive Experience | Profile | |
| Paul Bruno | Senior Development | Profile | |
| Bryan Stuart | CEO Pres | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.29) | Revenue Per Share 1.317 | Quarterly Revenue Growth 89.909 | Return On Assets (0.07) | Return On Equity (0.07) |
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.